How can we get close to zero? The potential contribution of biomedical prevention and the investment Framework towards an effective response to HIV

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Stover, John ^a,l   Hallett, Timothy B ^b   Wu, Zunyou ^c   Warren, Mitchell ^d,m   Gopalappa, Chaitra ^a   Pretorius, Carel ^a   Ghys, Peter D ^f,h   Montaner, Julio ^e   Schwartländer, Bernhard ^g,h   Gouws, Eleanor ^h   Garnett, Geoffrey ⁱ   Hallatt, Timothy ^b   Harmon, Thomas ^j   Holmes, Charles ^k,y   Barnabas, Ruanne ⁿ   Blandford, John ^c   Blecher, Mark ^o   Case, Kelsey ^b   Anderson, Sarah Jane ^b   Cremin, Ide ^b   Cherutich, Peter ^p   Dybul, Mark ^q,z   Costa, Amanda Rodrigues ^r   Gross, Martin ^s   Fisher, Kevin ^t   Grant, Robert ^u   Lima, Viviane ^e   Nosyk, Bohdan ^e   McGlynn, Margaret ^v   Solomon, Suniti ^w   Terris Prestholt, Fern ^x   more..

^a AVENIR HEALTH   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d AIDS Vaccine Advocacy Coalition   (United States)

^e BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^f UNAIDS   (Switzerland)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

^h UNAIDS   (India)

ⁱ BILL AND MELINDA GATES FOUNDATION   (United States)

^j INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^k US State Department Office of the Global AIDS Coordinator   (United States)

^l Futures Institute   (United States)

^m AVAC: Global Advocacy for HIV Prevention   (United States)

ⁿ UNIVERSITY OF WASHINGTON   (United States)

^o South African National Treasury   (South Africa)

^p National AIDS and STD Control Programme   (Kenya)

^q GEORGETOWN UNIVERSITY   (United States)

^r Georgetown University ^*  (Brazil)

^s Bill and Melinda Getes Foundation   (United States)

^t AVAC: Global Advocecy for HIV Prevention   (United States)

^u UNIVERSITY OF CALIFORNIA   (United States)

^v International AIDS Veccine Initiative   (United States)

^w YRG Care for AIDS Research and Education   (India)

^x LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^y Centre for Infectious Disease Research (CIDRZ)   (Zambia)

^z Global Fund to Fight HIV AIDS Tuberculosis and Malaria   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; DISEASE SURVEILLANCE; DRUG EFFECT; DRUG RESPONSE; EPIDEMIC; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RESOURCE ALLOCATION; TREATMENT PLANNING; VACCINATION; WORLD HEALTH ORGANIZATION; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH; HEALTH CARE PLANNING; HIV INFECTIONS; INVESTMENT; MEDICAL TECHNOLOGY; MORTALITY; PROCEDURES; QUALITY OF LIFE; SOCIOECONOMICS; THEORETICAL MODEL;

BIOMEDICAL TECHNOLOGY; COST-BENEFIT ANALYSIS; GLOBAL HEALTH; HEALTH RESOURCES; HIV INFECTIONS; HUMANS; INVESTMENTS; MODELS, THEORETICAL; MORTALITY; QUALITY OF LIFE; SOCIOECONOMIC FACTORS;

EID: 84910647881     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111956     Document Type: Article

References (28)

1. Schwartländer B, Stover J, Hallett T, Atun R, Avila C, et al. (2011) Towards and improved investment approach for an effective response to HV/AIDS. Lancet 377(9782):2031-2041. doi:10.1016/S0140-6736 (11) 60702-2
2. WHO (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization.
3. Hallet TB, Menzies NA, Revill P, Keebler D, Borquez A, et al. (2014) Using modeling to inform international guidelines for antiretroviral treatment. AIDS 28(Suppl 1), S1-4.
4. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, et al. (2014) Health benefits, cost, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health 2:e23-e34.
5. Hontelez J A C, Lune MN, Barnighausen T, Bakker R, Baltussen R, et al. (2013) Elimination of HIV in South Africa through Expanded Access to Antiretroviral Therapy: A Model Comparison Study. PLoS Med 10(10):e1001534. doi:10.1371/journal.pmed.1001534
6. Supervie V, Garcia-Lerma JG, Heneine W, Blower S (2010) HIV, transmitted drug resistance, and the paradox of pre-exposure prophylaxis. Proc Natl Sci USA 107(27):12381-6. doi:10.1073/pnas.1006061107
7. Pretorius C, Stover J, Bollinger L, Bacaer N, Williams B (2010) Evaluating the Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) and Its Impact on HIV-1 Transmission in South Africa. PLoS One 5(11):e13646. doi:10.1371/journal. pone.0013646
8. Vaccine (2011) Special issue on modeling the impact of HIV vaccines. Vaccine 18 August 2011, 29:36.
9. Stover J, Bollinger L, Hecht R, Williams C (2007) The Impact of an AIDS Vaccine in Developing Countries: A New Model and Initial Results Health Affairs 26:1147-1158.
10. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, et al. (2012) HIV Treatment as Prevention: Systematic Comparison of Mathematical Models of the Potential Impact of Antiretroviral Therapy on HIV Incidence in South Africa. PLoS Med 9(7):e1001245. doi:10.1371/journal.pmed.1001245
11. Futures Institute (2011) Goals Manual: A Model for Estimating the Effects of Interventions and Resource Allocation on HIV Infections and Deaths. Available at www. FuturesInstitute.org.
12. Montaner J (2011) Treatment as prevention-a double hat-trick. Lancet 378:208-209.
13. Nosyk B, Montaner J S G (2012) The Evolving Landscape of the Economics of HIV Treatment and Prevention. PLoS Med 9(2):e1001174. doi:10.1371/journal.pmed.1001174
14. Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, et al. (2013) Examining the evidence on the causal effect of highly active antiretroviral therapy on transmission of human immunodeficiency virus using the Bradford Hill criteria. AIDS 27(7):1159-65. doi:10.1097/QAD.0b013e32835f1d68
15. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (August 2011). Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365(6):493-505. doi:10.1056/NEJMoa1105243 PMC 3200068. PMID 21767103
16. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. on behalf of the CAPRISA 004 Trial Group (2010) Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 329(5996):1168-1174 doi:10.1126/science. 1193748
17. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men N Engl J Med 363(27):2587-2599.
18. Baeten JM, Donnell D, Ndase P, Mugo N, Campbell JD, et al. (2012) Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women N Engl J Med 367(5):399-410.
19. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med 367:423-34. doi:10.1056/NEJMoa1110711
20. Van Damme L (2012) The FEM-PrEP Trial of Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) among African Women. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 32LB.
21. Anticipating the Results of VOICE | Microbicide Trials Network [Internet]. [cited 24th Jan 2013]. Available at: http://www.mtnstopshiv.org/node/4667.
22. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 361(23):2209-2220. doi:10.1056/NEJMoa0908492
23. Sanofi-Pasteur "HIV Vaccines: Building on Success - RV144 Follow-Up Studies" Available at: http://www.sanofipasteur.com/sp-media/SP-CORP4/EN/161/2175/ANNEXE%201%20-%20P5%20Factsheet-FINAL.pdf Accessed January 17, 2013.
24. Burton DR, Poingnard P, Stanfield RL, Wilson IA (2012) Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337(6091):183-6.
25. Joint United Nations Programme on HIV/AIDS (2012) Global Report: UNAIDS Report on the Global AIDS Epidemic. UNAIDS: Geneva, Switzerland.
26. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, et al. (2013) How should HIV programmes respond to evidence for the benefits of earlier treatment initiation? A combined analysis of twelve mathermatical models. The Lancet Global Health Published online December 10, 2013 http://dx.doi.org/10.1016/S2214-109X(13)70172-4.
27. Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, et al. (2012) Comparison of Mathematical Models of the Potential Impact of Antiretroviral Therapy on HIV Incidence in South Africa. PLoS Med 9(7):e1001245. doi:10.1371/journal.pmed.1001245
28. Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, et al. (2013) The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS 17(3):447-458, January 28, 2013. doi:10.1097/QAD.0-b013e32835ca2dd